Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis - PubMed (original) (raw)

Review

Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis

Anca Trifan et al. World J Gastroenterol. 2017.

Abstract

Aim: To perform a systematic review and meta-analysis on proton pump inhibitors (PPIs) therapy and the risk of Clostridium difficile infection (CDI). METHODS We conducted a systematic search of MEDLINE/PubMed and seven other databases through January 1990 to March 2017 for published studies that evaluated the association between PPIs and CDI. Adult case-control and cohort studies providing information on the association between PPI therapy and the development of CDI were included. Pooled odds ratios (ORs) estimates with 95% confidence intervals (CIs) were calculated using the random effect. Heterogeneity was assessed by I2 test and Cochran's Q statistic. Potential publication bias was evaluated via funnel plot, and quality of studies by the Newcastle-Otawa Quality Assessment Scale (NOS).

Results: Fifty-six studies (40 case-control and 16 cohort) involving 356683 patients met the inclusion criteria and were analyzed. Both the overall pooled estimates and subgroup analyses showed increased risk for CDI despite substantial statistical heterogeneity among studies. Meta-analysis of all studies combined showed a significant association between PPI users and the risk of CDI (pooled OR = 1.99, CI: 1.73-2.30, P < 0.001) as compared with non-users. The association remained significant in subgroup analyses: by design-case-control (OR = 2.00, CI: 1.68-2.38, P < 0.0001), and cohort (OR = 1.98, CI: 1.51-2.59, P < 0.0001); adjusted (OR = 1.95, CI: 1.67-2.27, P < 0.0001) and unadjusted (OR = 2.02, CI: 1.41-2.91, P < 0.0001); unicenter (OR = 2.18, CI: 1.72-2.75, P < 0.0001) and multicenter (OR = 1.82, CI: 1.51-2.19, P < 0.0001); age ≥ 65 years (OR = 1.93, CI: 1.40-2.68, P < 0.0001) and < 65 years (OR = 2.06, CI: 1.11-3.81, P < 0.01). No significant differences were found in subgroup analyses (test for heterogeneity): P = 0.93 for case-control vs cohort, P = 0.85 for adjusted vs unadjusted, P = 0.24 for unicenter vs multicenter, P = 0.86 for age ≥ 65 years and < 65 years. There was significant heterogeneity across studies (I2 = 85.4%, P < 0.001) as well as evidence of publication bias (funnel plot asymmetry test, P = 0.002).

Conclusion: This meta-analysis provides further evidence that PPI use is associated with an increased risk for development of CDI. Further high-quality, prospective studies are needed to assess whether this association is causal.

Keywords: Clostridium difficile infection; Meta-analysis; Proton pump inhibitors; Risk; Systematic review.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors deny any conflict of interest.

Figures

Figure 1

Study selection process.

Figure 2

Forest plot of the meta-analysis.

Figure 3

Funnel plot with 95% confidence limits.

Cited by

EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
Biganzoli L, Cinieri S, Berardi R, Pedersini R, McCartney A, Minisini AM, Caremoli ER, Spazzapan S, Magnolfi E, Brunello A, Risi E, Palumbo R, Leo S, Colleoni M, Donati S, De Placido S, Orlando L, Pistelli M, Parolin V, Mislang A, Becheri D, Puglisi F, Sanna G, Zafarana E, Boni L, Mottino G. Biganzoli L, et al. Breast Cancer Res. 2020 Aug 5;22(1):83. doi: 10.1186/s13058-020-01319-1. Breast Cancer Res. 2020. PMID: 32758299 Free PMC article. Clinical Trial.
Key Considerations From a Health Authority Perspective When Proton Pump Inhibitors Are Used to Treat Gastroesophageal Reflux Disease (GERD) and Their Implications.
Meyer JC, MacBride-Stewart S, Fadare JO, Abdulrahman Jairoun A, Haque M, Massele A, Kumar S, Sefah IA, P Skosana P, Godman B. Meyer JC, et al. Cureus. 2022 Nov 26;14(11):e31918. doi: 10.7759/cureus.31918. eCollection 2022 Nov. Cureus. 2022. PMID: 36447806 Free PMC article. Review.
Healthcare associated Clostridioides difficile infection in adult surgical and medical patients hospitalized in tertiary hospital in Belgrade, Serbia: a seven years prospective cohort study.
Šuljagić V, Milenković B, Perić A, Jovanović D, Begović-Kuprešanin V, Starčević S, Tomić A, Vezmar Kovačević S, Dragojević-Simić V. Šuljagić V, et al. Libyan J Med. 2020 Dec;15(1):1708639. doi: 10.1080/19932820.2019.1708639. Libyan J Med. 2020. PMID: 31905110 Free PMC article.
Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study.
Kuo CJ, Lin CY, Chen CW, Hsu CY, Hsieh SY, Chiu CT, Lin WR. Kuo CJ, et al. J Pers Med. 2021 Oct 22;11(11):1063. doi: 10.3390/jpm11111063. J Pers Med. 2021. PMID: 34834415 Free PMC article.
Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis.
Ma YJ, Cao ZX, Li Y, Feng SY. Ma YJ, et al. World J Gastroenterol. 2019 Jun 7;25(21):2675-2682. doi: 10.3748/wjg.v25.i21.2675. World J Gastroenterol. 2019. PMID: 31210718 Free PMC article.

References

1. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol. 2010;4:409–416. - PubMed
1. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM. Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC Infect Dis. 2011;11:194. - PMC - PubMed
1. Kurti Z, Lovasz BD, Mandel MD, Csima Z, Golovics PA, Csako BD, Mohas A, Gönczi L, Gecse KB, Kiss LS, et al. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. World J Gastroenterol. 2015;21:6728–6735. - PMC - PubMed
1. Honda H, Dubberke ER. The changing epidemiology of Clostridium difficile infection. Curr Opin Gastroenterol. 2014;30:54–62. - PubMed
1. Dubberke ER, Butler AM, Yokoe DS, Mayer J, Hota B, Mangino JE, Khan YM, Popovich KJ, Fraser VJ. Multicenter study of Clostridium difficile infection rates from 2000 to 2006. Infect Control Hosp Epidemiol. 2010;31:1030–1037. - PMC - PubMed

Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis - PubMed (original) (raw)